Karyopharm Therapeutics Inc. announced a private placement of first lien senior secured term loan facility for the gross proceeds of $100 million on May 8, 2024. The transaction included participation from certain holders of the 2025 Convertible Notes providing $85.0 million and a new lender, HCRx, providing $15.0 million. The Secured Term Loan matures in 8 May 2028 and accrues interest at a rate of Secured Overnight Financing Rate (SOFR) plus 9.25%.

Amortization payments will commence 24 months after closing.